Lexaria Bioscience Corp.
LEXX
$1.35
$0.032.27%
| Weiss Ratings | LEXX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | LEXX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | LEXX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.12 | |||
| Price History | LEXX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -2.17% | |||
| 30-Day Total Return | -23.73% | |||
| 60-Day Total Return | -37.50% | |||
| 90-Day Total Return | -41.81% | |||
| Year to Date Total Return | -41.30% | |||
| 1-Year Total Return | -65.38% | |||
| 2-Year Total Return | -50.18% | |||
| 3-Year Total Return | -57.01% | |||
| 5-Year Total Return | -84.13% | |||
| 52-Week High % Change | -69.59% | |||
| 52-Week Low % Change | 17.39% | |||
| Price | LEXX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $4.44 | |||
| 52-Week Low Price | $1.15 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | Jun 03, 2024 | |||
| Valuation | LEXX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 23.70M | |||
| Enterprise Value | 15.33M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.49 | |||
| Earnings Per Share Growth | -43.62% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 45.30 | |||
| Price/Book (Q) | 2.41 | |||
| Enterprise Value/Revenue (TTM) | 30.85 | |||
| Price | $1.35 | |||
| Enterprise Value/EBITDA (TTM) | -2.14 | |||
| Enterprise Value/EBIT | -2.12 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | LEXX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 16.67M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | LEXX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 250 765 6424 | |||
| Address | 740 McCurdy Road Kelowna, BC V1X 2P7 | |||
| Website | lexariabioscience.com | |||
| Country | Canada | |||
| Year Founded | 2004 | |||
| Profitability | LEXX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -1,458.40% | |||
| Profit Margin | -1,473.07% | |||
| Management Effectiveness | LEXX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -67.50% | |||
| Return on Equity | -- | |||
| Income Statement | LEXX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 496.90K | |||
| Total Revenue (TTM) | 496.90K | |||
| Revenue Per Share | $0.03 | |||
| Gross Profit (TTM) | 494.20K | |||
| EBITDA (TTM) | -7.17M | |||
| EBIT (TTM) | -7.25M | |||
| Net Income (TTM) | -7.32M | |||
| Net Income Avl. to Common (TTM) | -7.32M | |||
| Total Revenue Growth (Q YOY) | 21.55% | |||
| Earnings Growth (Q YOY) | -128.41% | |||
| EPS Diluted (TTM) | -0.49 | |||
| EPS Diluted Growth (Q YOY) | -24.48% | |||
| Balance Sheet | LEXX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 8.12M | |||
| Cash Per Share (Q) | $0.49 | |||
| Total Current Assets (Q) | 8.83M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 9.39M | |||
| Current Ratio (Q) | 29.636 | |||
| Book Value Per Share (Q) | $0.56 | |||
| Total Assets (Q) | 9.79M | |||
| Total Current Liabilities (Q) | 297.80K | |||
| Total Debt (Q) | 130.70K | |||
| Total Liabilities (Q) | 399.70K | |||
| Total Common Equity (Q) | 9.77M | |||
| Cash Flow | LEXX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -186.40K | |||
| Cash from Financing (TTM) | 12.84M | |||
| Net Change in Cash (TTM) | 6.12M | |||
| Levered Free Cash Flow (TTM) | -4.28M | |||
| Cash from Operations (TTM) | -6.50M | |||
